Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Duchenne Muscular Dystrophy: Second Product Isn't The Charm

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA reviewers say patients treated with Sarepta's eteplirsen seemed to follow similar disease course as Duchenne muscular dystrophy natural history, casting doubts on product's approvability.


Related Content

Sarepta Should Gain Clean Slate With CBER Review of DMD Gene Therapy
How Do You Solve A Problem Like Biopsy In Alcohol-Associated Liver Disease?
Rare Diseases: Growing Understanding Will Unlock Accelerated Approval, FDA Says
Sarepta Complained To Woodcock About Exondys 51 Review Early And Often
Woodcock's 'Bias' In Sarepta Case Made Jenkins Worry About Future Drug Reviews
Sarepta Trial Protocol Changes May Ignite Debate On Placebo Design
Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review
Exondys 51’s Development: Was Placebo-Controlled Trial Possible?
Sarepta Pressured FDA On Eteplirsen Due To ‘Dire’ Finances, Gave Investors Rosier Picture
BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts